Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 2/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732106 | 0.89 | ALDH1A1 (0.47) | SMN1; SMN2PTPN2PTPN1HDAC6HDAC3 | |
| SCHEMBL3735481 | 0.88 | PTPN1 (0.44) | ESRRGSMN1; SMN2MAPTPTPN2PTPN1 | |
| SCHEMBL3745586 | 0.88 | PTPN1 (0.42) | ESRRGNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3743388 | 0.88 | KMT2A (0.47) | SMN1; SMN2MAPTLMNAMEN1GAA | |
| SCHEMBL3736642 | 0.87 | LMNA (0.45) | MAPTHDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL3737634 | 0.86 | CA1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTHDAC2 | |
| SCHEMBL3738509 | 0.85 | TRPV1 (0.51) | HDAC2HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL3737269 | 0.85 | PTPN1 (0.59) | ESRRGNPC1RAB9AMLYCDPTPN2 | |
| SCHEMBL3738761 | 0.84 | CA2 (0.41) | ESRRGMAPTPTPN1LMNA | |
| SCHEMBL3737787 | 0.84 | TRPV1 (0.47) | HDAC2HDAC8HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1812012-A2 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Ceptyr, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | FALCON TECHNOLOGY PARTNERS L.P. | 2006-06-29 | — | — | US | disclosed |
| WO-2006055525-A2 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | ESRRG 2947/4885NPC1 1382/4885RAB9A 2896/4885 |
| US-20060142250-A1 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PPM1B, PTPN1, PTPN5 | ESRRG 2947/4885NPC1 1382/4885RAB9A 2896/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | ESRRG 2947/4885NPC1 1382/4885RAB9A 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.